Details for 2019213030

Up to date per 01.04.2026

Actions

Title / Product Name

ANTI-CD38-ANTIKÖRPER UND FUSIONEN DAVON MIT ABGESCHWÄCHTEM INTERFERON-ALPHA-2B

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2019213030

EP Publication Number

3677591

E-Number

1540428

Language

PCT Number

Publication Date

08.07.2020 A

28.12.2022 B1

Registration Date

28.12.2022

AT Publication Date

15.01.2023

Application Date

29.04.2013

Registration Number

Priorities

IPC

C07K 14/56 20060101AFI20220217BHEP

Maximum Duration of Protection

29.04.2033

Owner

Teva Pharmaceuticals Australia Pty LtdLevel 2 37 Epping Road Macquarie Park, NSW 2113AU

Representative

Häupl & Ellmeyer KG, PatentanwaltskanzleiMariahilfer Straße 50 (Kirchengasse 1)1070 WienAT

Inventor

CLARKE, Adam37 Epping Road, Level 2 Macquarie Park NSW 2113AU

POLLARD, Matthew37 Epping Road, Level 2 Macquarie Park NSW 2113AU

DOYLE, Anthony, Gerard37 Epping Road, Level 2 Macquarie Park NSW 2113AU

BEHRENS, Collette37 Epping Road, Level 2 Macquarie Park NSW 2113AU

YAMAGISHI, Tetsuo37 Epping Road, Level 2 Macquarie Park NSW 2113AU

WILSON, David, S. Jr.610 Galveston Drive Redwood City, California 94063US

POGUE, Sarah, L.241 Barton Dr. Fremont, California 94536-1703US

TAURA, Tetsuya514 Driscoll Place Palo Alto, California 94306US

Information about Fees